Related Articles
Combination chemotherapy with TAS‑102 plus bevacizumab in salvage‑line treatment of metastatic colorectal cancer: A single‑center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage‑line therapy of metastatic colorectal cancer
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival
Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype
Polymorphisms of GSTP1, ERCC2 and TS‑3'UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients
Safety and efficacy of panitumumab therapy after metastatic colorectal cancer progression with cetuximab: Experience at a single Japanese institution